Interferon beta-1a: Clinical Trials

16 trials of Interferon beta-1a, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 1 unknown, 1 withdrawn. 16 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 14, Unknown 1, Withdrawn 1
Phase 21Withdrawn 1

Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnFred Hutchinson Cancer Center2025-04-012024-07-12
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products
Interferon beta-1a, Peginterferon beta-1a, Placebo - Healthy Subjects, Pharmacokinetics
Phase 1CompletedFood and Drug Administration (FDA)842020-02-282024-04-22
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
Interferon Beta-1A - Bioequivalence, Healthy
Phase 1CompletedCinnagen402017-11-272020-01-10
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
Rebif®, Avonex - Relapsing-remitting Multiple Sclerosis
Phase 1UnknownPD Dr. Marcus Müller502015-01-012016-06-03
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
peginterferon beta-1a, Rebif - Multiple Sclerosis
Phase 1CompletedBiogen302014-10-012015-02-02
Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers
BCD-054, Rebif, Avonex - Healthy
Phase 1CompletedBiocad602014-07-012017-04-10
Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers
Interferon beta-1a - Healthy
Phase 1CompletedBiocad322013-02-012016-05-04
Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers
Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS) - Multiple Sclerosis
Phase 1CompletedBiogen1102012-01-012012-11-19
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects
Avonex - Healthy
Phase 1CompletedBiogen242011-08-012011-11-04
Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects
Interferon beta-1a - Healthy
Phase 1CompletedAzidus Brasil202011-01-012013-02-25
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
Avonex - Healthy Volunteers
Phase 1CompletedBiogen1202010-05-052017-11-17
Phase I BP Interferon (IFN) Beta-004
Interferon beta-1a HSA-free biosimilar, Interferon beta-1a HSA+ biosimilar, Interferon beta-1a original - Multiple Sclerosis, Relapsing-Remitting
Phase 1CompletedCentre Hospitalier Universitaire Vaudois242006-05-012015-08-10
Phase I BP Interferon (IFN) Beta-001
Interferon beta-1a - Multiple Sclerosis, Relapsing-Remitting
Phase 1CompletedCentre Hospitalier Universitaire Vaudois122005-05-012015-08-06
Safety Study of Interferon Beta 1a to for Acute Stroke
Interferon beta-1a - Cerebrovascular Accident
Phase 1CompletedNational Institute of Neurological Disorders and Stroke (NINDS)602004-11-172017-07-02
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Serum containing Avonex, Serum Free Avonex - Multiple Sclerosis
Phase 1CompletedBiogen962003-08-012009-06-04
Avonex®: Safety, Blood Levels and Effects
Interferon beta 1a, (IM) AVONEX® - Multiple Sclerosis (MS)
Phase 1CompletedTrio Medicines Ltd.772001-01-012013-05-27

Conditions studied

Multiple Sclerosis (4)  ·  Multiple Sclerosis, Relapsing-Remitting (3)  ·  Burkitt Lymphoma (1)  ·  Inflammation (1)  ·  Ischemia (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Respiratory Aspiration (1)  ·  Stroke (1)

Sponsors

Biogen (5)  ·  Biocad (2)  ·  Centre Hospitalier Universitaire Vaudois (2)  ·  Azidus Brasil (1)  ·  Cinnagen (1)  ·  Food and Drug Administration (FDA) (1)  ·  Fred Hutchinson Cancer Center (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  PD Dr. Marcus Müller (1)  ·  Trio Medicines Ltd. (1)

Countries

United States (6)  ·  Russia (2)  ·  Brazil (1)  ·  China (1)  ·  Finland (1)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

Ivan Sardaryan, PhD (2)  ·  Carlos Sanabria, MD (1)  ·  Jordan Gauthier (1)  ·  Mika Scheinin, MD, PhD (1)  ·  Steve Warrington (1)

Results publications

PMID 27423899, PMID 21988668, PMID 26392348, PMID 27060836, PMID 41420638

NIH funding

2016 (1)